ETR:MORMorphoSys Stock Price, Forecast & News

€116.90

+1.05 (+0.91 %)

(As of 07/13/2020 04:00 PM ET)

Add

Compare

Today's Range

€113.60

Now: €116.90▼

€116.90

50-Day Range

€103.90

MA: €114.94▼

€121.80

52-Week Range

€65.25

Now: €116.90▼

€146.30

Volume107,627 shs

Average Volume153,687 shs

Market Capitalization$3.82 billion

P/E Ratio32.19

Dividend YieldN/A

BetaN/A

MorphoSys AG, together with its subsidiaries, develops and commercializes antibodies and peptides for therapeutic applications in the United States. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 115 drugs for various diseases, such as psoriasis, Alzheimer's diseases, haematological malignancies, solid tumors, hemophilia, multiple myeloma, metabolic diseases, inflamation, thrombosis, brittle bone syndrome, eye diseases, cancers, diabetic eye diseases, blood disorders, and asthma. Its product pipeline includes MOR208, an antibody for the treatment of haematological cancers; MOR202, an antibody for the treatment of multiple myeloma and other cancers, as well as other autoimmune diseases; MOR106, an antibody for rheumatoid arthritis; and MOR107, a lanthipeptide for oncology diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize MOR202 in China, Taiwan, Hong Kong, and Macao; and a strategic alliance with the LEO Pharma A/S to develop peptide-derived therapeutics for unmet medical needs. The company was founded in 1992 and is headquartered in Planegg, Germany.

Beat the Market (BTM) Rank^™

2.3 Analyst's Opinion

Consensus Rating
MorphoSys has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of €124.13, MorphoSys has a potential upside of 6.2% from its current price of €116.90.
Amount of Analyst Coverage
MorphoSys has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.8 Community Rank

Outperform Votes
MorphoSys has received 300 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
MorphoSys has received 233 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
MorphoSys has received 56.29% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about MorphoSys and other stocks. Vote “Outperform” if you believe MOR will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
MorphoSys does not currently pay a dividend.
Dividend Growth
MorphoSys does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MorphoSys insiders have not sold or bought any company stock.

0.6 Earnings and Valuation

Earnings Growth
Earnings for MorphoSys are expected to grow in the coming year, from (€2.26) to €0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MorphoSys is 32.19, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.76.
Price to Earnings Ratio vs. Sector
The P/E ratio of MorphoSys is 32.19, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 29.08.
Price to Book Value per Share Ratio
MorphoSys has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.15 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ETR

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolETR:MOR

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.morphosys.de

Phone+49-89-899270

Debt

Debt-to-Equity Ratio7.16

Current Ratio12.87

Quick Ratio12.74

Price-To-Earnings

Trailing P/E Ratio32.19

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$309.43 million

Price / Sales12.34

Cash Flow€31.89 per share

Price / Cash Flow3.67

Book Value€20.47 per share

Price / Book5.71

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees329

Outstanding Shares32,664,200

Market Cap$3.82 billion

Next Earnings Date8/5/2020 (Estimated)

OptionableNot Optionable

Receive MOR News and Ratings via Email

Sign-up to receive the latest news and ratings for MOR and its competitors with MarketBeat's FREE daily newsletter.

MorphoSys (ETR:MOR) Frequently Asked Questions

How has MorphoSys' stock been impacted by COVID-19 (Coronavirus)?

MorphoSys' stock was trading at €91.05 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MOR shares have increased by 28.4% and is now trading at €116.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of MorphoSys?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MorphoSys in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for MorphoSys.

When is MorphoSys' next earnings date?

MorphoSys is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for MorphoSys.

What price target have analysts set for MOR?

8 Wall Street analysts have issued twelve-month target prices for MorphoSys' shares. Their forecasts range from €105.00 to €150.00. On average, they anticipate MorphoSys' share price to reach €124.13 in the next twelve months. This suggests a possible upside of 6.2% from the stock's current price. View analysts' price targets for MorphoSys.

Has MorphoSys been receiving favorable news coverage?

Media coverage about MOR stock has trended very negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MorphoSys earned a news sentiment score of -3.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the near future. View the latest news about MorphoSys.

Who are some of MorphoSys' key competitors?

Some companies that are related to MorphoSys include Vir Biotechnology (VIR), BTG (BTG), Cronos Group (CRON), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Viela Bio (VIE), Mesoblast (MSB), Polynovo (PNV), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU), Trillium Therapeutics (TRIL) and PureTech Health (PRTC). View all competitors.

What other stocks do shareholders of MorphoSys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MorphoSys investors own include Novo Nordisk A/S (NVO), Supernus Pharmaceuticals (SUPN), Akari Therapeutics (AKTX), Gilead Sciences (GILD), Nightstar Therapeutics (NITE), Solaredge Technologies (SEDG), Teva Pharmaceutical Industries (TEVA), Allergan (AGN), Avadel Pharmaceuticals (AVDL) and Fresenius Medical Care AG & Co. (FMS).

Who are MorphoSys' key executives?

MorphoSys' management team includes the following people:

Dr. Simon E. Moroney, Chairman of Management Board & CEO (Age 59)
Mr. Jens H. Holstein, CFO & Member of Management Board (Age 55)
Dr. Markus Enzelberger, Chief Scientific Officer & Member of Management Board (Age 49)
Dr. Malte Peters, Chief Devel. Officer & Member of Management Board (Age 57)
Mr. Klaus De Wall, Head of Accounting & Tax

What is MorphoSys' stock symbol?

MorphoSys trades on the ETR under the ticker symbol "MOR."

What is MorphoSys' stock price today?

One share of MOR stock can currently be purchased for approximately €116.90.

How big of a company is MorphoSys?

MorphoSys has a market capitalization of $3.82 billion and generates $309.43 million in revenue each year. MorphoSys employs 329 workers across the globe.

What is MorphoSys' official website?

The official website for MorphoSys is www.morphosys.de.

How can I contact MorphoSys?

MorphoSys' mailing address is Semmelweisstr. 7, PLANEGG, 82152, Germany. The company can be reached via phone at +49-89-899270.

This page was last updated on 7/13/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings